

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 20, 2025

EL4

RRID:CVCL_0255

Type: Cell Line

Proper Citation

(RCB Cat# RCB1641, RRID:CVCL_0255)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0255

Proper Citation: (RCB Cat# RCB1641, RRID:CVCL_0255)

Sex: Sex unspecified

Defining Citation: [PMID:4099030](#), [PMID:4867923](#), [PMID:14801344](#), [PMID:30084848](#)

Comments: Omics: HLA class I peptidome analysis by proteomics., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

Category: Cancer cell line

Name: EL4

Synonyms: EL-4, EL 4, E.L.4

Cross References: BTO:BTO_0003432, CLO:CLO_0002913, CLO:CLO_0050166, EFO:EFO_0022736, MCCL:MCC:0000146, CLDB:cl1158, CLDB:cl1159, CLDB:cl1160, ATCC:TIB-39, BCRC:60179, CCRID:1101MOU-PUMC000136, CCRID:3101MOUTCM41, CCRID:4201MOU-CCTCC00136, CCTCC:GDC0136, ChEMBL-Cells:ChEMBL3308380, ChEMBL-Targets:ChEMBL614293, CLS:300653, DSMZ:ACC-831, DSMZCellDive:ACC-831, ECACC:85023105, JCRB:IFO50027, JCRB:JCRB1350, KCB:KCB 2013027YJ, KCLB:40039, Lonza:760, NCBI_Iran:C114, PRIDE:PXD008733, PubChem_Cell_line:CVCL_0255, RCB:RCB1641, TKG:TKG 0150, Wikidata:Q54832230

ID: CVCL_0255

Vendor: RCB

Catalog Number: RCB1641

Record Creation Time: 20220427T215832+0000

Record Last Update: 20250420T105949+0000

Ratings and Alerts

No rating or validation information has been found for EL4.

Warning: Discontinued: JCRB; IFO50027

Omics: HLA class I peptidome analysis by proteomics., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 404 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Ward GA, et al. (2024) Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma. Cancer research communications, 4(6), 1441.

Liu Y, et al. (2024) Squalene-epoxidase-catalyzed 24(S),25-epoxycholesterol synthesis promotes trained-immunity-mediated antitumor activity. Cell reports, 43(4), 114094.

Schmidt D, et al. (2024) Oncogenic Calreticulin Induces Immune Escape by Stimulating TGF β Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment. Cancer research, 84(18), 2985.

Wolf SP, et al. (2024) One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(8), 1642.

Sun X, et al. (2024) Deletion of the mRNA endonuclease Regnase-1 promotes NK cell anti-tumor activity via OCT2-dependent transcription of Ifng. Immunity, 57(6), 1360.

Kim HY, et al. (2024) Specific targeting of cancer vaccines to antigen-presenting cells via an endogenous TLR2/6 ligand derived from cysteinyl-tRNA synthetase 1. Molecular therapy : the journal of the American Society of Gene Therapy, 32(10), 3597.

Sim MJW, et al. (2024) Identification and structural characterization of a mutant KRAS-G12V

specific TCR restricted by HLA-A3. *European journal of immunology*, e2451079.

Mandula JK, et al. (2024) Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages. *Immunity*, 57(5), 1124.

Nishi W, et al. (2023) Evaluation of therapeutic PD-1 antibodies by an advanced single-molecule imaging system detecting human PD-1 microclusters. *Nature communications*, 14(1), 3157.

Zhang ZT, et al. (2023) Dexmedetomidine alleviates acute lung injury by promoting Tregs differentiation via activation of AMPK/SIRT1 pathway. *Inflammopharmacology*, 31(1), 423.

Kim J, et al. (2023) Discovery of Myeloid-Derived Suppressor Cell-Specific Metabolism by Metabolomic and Lipidomic Profiling. *Metabolites*, 13(4).

Soh S, et al. (2023) Adiponectin affects the migration ability of bone marrow-derived mesenchymal stem cells via the regulation of hypoxia inducible factor 1?. *Cell communication and signaling : CCS*, 21(1), 158.

Finisguerra V, et al. (2023) Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression. *Journal for immunotherapy of cancer*, 11(5).

Gracheva IA, et al. (2023) Design, Synthesis and In Vitro Biological Activity of Novel C-7 Methylene Congeners of Furanoalcolchicinoids. *Pharmaceutics*, 15(4).

Rietdijk S, et al. (2023) Characterization of Ly108-H1 Signaling Reveals Ly108-3 Expression and Additional Strain-Specific Differences in Lupus Prone Mice. *International journal of molecular sciences*, 24(5).

Bourne CM, et al. (2023) Host-cell Interactions of Engineered T cell Micropharmacies. *bioRxiv : the preprint server for biology*.

Tarasenko TN, et al. (2023) Pyruvate dehydrogenase complex integrates the metabolome and epigenome in memory T cell differentiation in vitro. *Research square*.

Ren L, et al. (2023) CBX4 promotes antitumor immunity by suppressing Pdcd1 expression in T cells. *Molecular oncology*, 17(12), 2694.

Miyauchi S, et al. (2023) Reprogramming of tumor-associated macrophages via NEDD4-mediated CSF1R degradation by targeting USP18. *Cell reports*, 42(12), 113560.

Richard AC, et al. (2023) Cytotoxic T lymphocytes require transcription for infiltration but not target cell lysis. *EMBO reports*, 24(11), e57653.